Friday 6 November 2026 Export LFMD’s income statement to Excel — free account

LifeMD, Inc.

LFMD Healthcare Health Information Services

LifeMD, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $194.1 million, up 25.3% from fiscal 2024.

Revenue: −3.55%
EPS: −166.7%
Free cash flow: −247.5%

Quarter to June 2026, against a year earlier

Revenue growth 5 yrs

2.36 0.07 +3.06%

Follow LFMD

Alert me

Market cap: $110.4M
P/E: 0.0×
Fwd P/E: −4.4×
Dividend yield: —
F-score: 6/9
Altman Z: −0.02
Beneish M: −3.67
Dividend safety: n/a

Overview

Insider Decisions last twelve months

Sold, $m 0.05

Trades a month
	Jan 26			Apr 26			Jul 26			Oct 26
Buy	—	—	—	—	—	—	—	—	—	—	—	—
Sell	1	—	—	—	—	—	—	—	—	—	—	—

Insider Ownership 18.03%

Capital & Financial Ratios $m

Size

Market Cap 110.38

Revenue ttm 191.59

Net income ttm 0.43

Free cash flow ttm (18.28)

Net debt Q (25.14)

Valuation

P/E 0.00

Forward P/E (4.42)

Price / sales 0.59

Forward P/S Powerpack

Price / FCF 0.00

Price / book 14.16

Financial health

Current ratio Q 0.90

Debt / equity Q 0.00

Interest coverage Q 158.04

Growth

Revenue growth Q −3.55%

Operating income growth Q −203.79%

EPS, this year −307.43%

EPS, next year A +82.37%

Revenue, next year A +6.98%

EPS, past 5 yrs —

EPS, next 5 yrs A −15.28%

Green and red mark values outside typical ranges; (Q) is the latest quarter, (A) analysts’ estimates. How we judge →

Valuation vs history

EV/Sales, ten years

P/S against its own 10 years 9.90%

10-year low 10-year high

P/B against its own 10 years 34.57%

10-year low 10-year high

EV/Sales against its own 10 years 11.36%

10-year low 10-year high

Dividends

Yield: —
Annual rate: —
Payout ratio: —

Assets vs Liabilities $m

	2023	2024	2025	Q'26
Cash	33	33	37	25
Receivables	5	10	9	11
Inventory	3	3	3	3
Other	1	3	3	3
	43	52	52	42

	2023	2024	2025	Q'26
Payables	11	11	14	18
ST’ Debt	—	8	—	—
Other	—	—	—	—
	35	67	42	47

Compound Annual Growth %

	10y	5y	3y
Sales	66.03%	39.08%	17.69%
Cash Flow	0.00%	0.00%	0.00%
Earnings	0.00%	0.00%	0.00%
Book Value	62.44%	0.00%	0.00%

Earnings Trends EPS, adjusted, against the consensus

Q2 FY26 Estimate −0.20 Actual −0.16

−0.23 −0.17 −0.11 −0.04 0.02

Q3 FY25 Miss −0.04

Q4 FY25 Miss −0.03

Q1 FY26 Miss −0.06

Q2 FY26 Beat +0.04

Q3 FY26 — Nov 9

Earnings per share against the consensus, by quarter
Quarter	Estimate	Reported	Result
Q3 FY25	−0.06	−0.10	Miss by 0.04
Q4 FY25	−0.01	−0.04	Miss by 0.03
Q1 FY26	−0.14	−0.20	Miss by 0.06
Q2 FY26	−0.20	−0.16	Beat by 0.04
Q3 FY26	−0.14	—	Reports 9 November 2026

EPS $

	Mar	Jun	Sep	Dec	Year
’26	(0.20)	(0.16)	—	—	—
’25	0.01	(0.06)	(0.10)	0.41	0.25
’24	(0.19)	(0.19)	(0.14)	(0.14)	(0.60)
’23	(0.15)	(0.23)	(0.20)	(0.12)	(0.70)
’22	(0.46)	(0.45)	(0.26)	(0.40)	(1.57)
’21	(0.47)	(0.64)	(0.54)	(0.62)	(2.29)
’20	(0.25)	(0.30)	(1.65)	(2.56)	(4.44)

Fiscal quarters ending in the months shown.

Revenue $m

	Mar	Jun	Sep	Dec	Year
’26	50	47	—	—	—
’25	51	49	60	34	194
’24	44	51	53	7	155
’23	33	36	39	45	153
’22	29	30	31	28	119
’21	18	22	25	27	93
’20	4	9	11	13	37

Fiscal quarters ending in the months shown.

Operating Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	0	(7)	—	—	—
’25	3	9	0	(3)	8
’24	5	5	7	1	18
’23	(3)	5	1	6	9
’22	(8)	(10)	(3)	(2)	(23)
’21	(9)	(11)	(7)	(6)	(33)
’20	1	(2)	(4)	(7)	(12)

Fiscal quarters ending in the months shown.

Free Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(2)	(9)	—	—	—
’25	1	6	(5)	(3)	(1)
’24	3	1	3	2	9
’23	(4)	2	(1)	3	0
’22	(14)	(13)	(5)	(4)	(36)
’21	(9)	(12)	(8)	(7)	(36)
’20	1	(2)	(5)	(7)	(13)

Fiscal quarters ending in the months shown.

Group	Line	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	TTM Jun ’26	Trend	10 yrs	2026e	2027e	2028e	Next 3/yr
													Ten-year view		Analyst estimates Powerpack
Income, $m
Income, $m	Revenue	5	4	8	12	37	93	119	153	155	194	192		+49.4%	208	245	282	+13.3%
	Gross margin, %	62.85	72.36	76.02	79.75	76.24	80.62	84.32	87.61	86.15	85.72	87.50		+22.9 pt	Powerpack LifeMD, Inc.’s next three years, line by line Analysts expect revenue to grow 13.3% a year to 2028 — slower than the 49.4% of the last 9 years. See the consensus for every other line: earnings, margins, cash flow, valuation and returns. Unlock estimates Try Powerpack free for 7 days, then $99 / year ($8.25 a month). Cancel any time. Also in Powerpack: every quarter, Excel exports, API & MCP access. Compare plans
	EBT	(1)	(1)	(2)	(4)	(60)	(61)	(45)	(17)	(23)	(10)	(21)		+26.6%
	EBT margin, %	(23.35)	(37.46)	(28.96)	(29.28)	(161.96)	(66.02)	(37.52)	(11.41)	(14.58)	(5.25)	(11.22)		+18.1 pt
	Net income	(1)	(1)	(1)	(4)	(61)	(61)	(45)	(18)	(21)	16	0		n/m
Per share, $
Per share, $	Revenue	0.78	0.44	0.94	1.26	2.61	3.44	3.84	4.50	3.76	4.30	4.01		+20.8%
	Earnings	(0.17)	(0.15)	(0.10)	(0.35)	(4.44)	(2.29)	(1.57)	(0.70)	(0.60)	0.25	(0.05)		n/m
	Cash flow	(0.06)	(0.10)	(0.10)	0.03	(0.85)	(1.22)	(0.74)	0.26	0.43	0.18	(0.21)		n/m
	Capex	0.00	0.00	(0.01)	0.00	(0.03)	(0.13)	(0.42)	(0.26)	(0.20)	(0.21)	(0.18)		n/m
	Free cash flow	(0.06)	(0.10)	(0.11)	0.03	(0.88)	(1.35)	(1.16)	0.00	0.23	(0.03)	(0.38)		(8.5%)
	Book value	(0.05)	0.07	0.09	(0.11)	(0.06)	0.96	(0.24)	0.16	(0.18)	0.51	0.17		n/m
	Shares, m	7	8	9	10	14	27	31	34	41	45	47		+23.6%
Valuation, ×
Valuation, ×	P/E	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	13.12	0.00		1.3
	P/S	1.53	4.08	0.74	0.46	2.50	1.13	0.49	1.87	1.32	0.79	0.59		1.5
	P/B	0.00	24.13	7.55	0.00	0.00	4.81	0.00	51.35	0.00	6.65	14.16		9.4
	EV/Sales	1.52	4.07	0.73	0.44	2.28	0.70	0.49	1.78	1.22	0.68	0.54		1.4
	EV/FCF	(19.50)	(18.34)	(6.70)	21.79	(6.76)	(1.78)	(1.64)	3,127.18	20.37	(106.73)	(5.64)		300.8
Cash, $m
Cash, $m	Operating cash flow	0	(1)	(1)	0	(12)	(33)	(23)	9	18	8	(10)		n/m
	Capex	—	—	0	—	0	(3)	(13)	(9)	(8)	(10)	(8)		+91.7%
	Free cash flow	0	(1)	(1)	0	(13)	(36)	(36)	0	9	(1)	(18)		+13.1%
Balance, $m
Balance, $m	Working capital	0	1	0	(1)	(2)	22	(20)	8	(15)	10	(5)		n/m
	Net debt	0	0	0	0	(8)	(39)	0	(15)	(14)	(37)	(25)		+96.9%
	Shareholders’ equity	0	1	1	(1)	(1)	26	(7)	6	(8)	23	8		n/m
Returns, %
Returns, %	ROA	(178.87)	(117.45)	(63.96)	(103.50)	(752.12)	(195.08)	(128.70)	(56.34)	(36.43)	15.35	(4.35)		+194.2 pt
	ROIC	0.00	(118.32)	(144.88)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00		0.0 pt
	ROE	1,225.79	(923.78)	(172.03)	2,027.27	2,260.22	(716.97)	(988.99)	751.79	2,465.96	144.18	(69.60)		(1,081.6) pt
People
People	Employees	11	10	16	26	56	232	220	232	336	389	—		+48.6%
	Revenue/emp, $m	0.48	0.37	0.52	0.48	0.67	0.40	0.54	0.66	0.46	0.50	—		+0.5%

Negative figures in brackets.

estimates

All 10 years →

Fiscal years to Dec 2025 · latest quarter Jun 2026 · fundamentals updated 26 Oct 2026

Company	Market cap	P/E	Fwd P/E	Revenue growth (Q)	EPS growth (Q)	FCF growth (Q)	Gross margin (Q)	EBIT margin (Q)	Compare
CTEV Claritev Corporation	$342.7M	— (loss-making)	— (loss-making)	+6.59% (above 0%: growing)	n/m	+49.10% (above 0%: growing)	73.72%	9.09%	Compare
SPOK Spok Holdings, Inc.	$245.9M	12.9×	16.2×	−2.56% (below 0%: shrinking)	+190.31% (above 0%: growing)	+61.57% (above 0%: growing)	79.66%	17.08%	Compare
AMWL American Well Corporation	$208.5M	— (loss-making)	— (loss-making)	−12.96% (below 0%: shrinking)	n/m	+21.98% (above 0%: growing)	52.99%	(23.79%)	Compare
SY So-Young International Inc. Sponsored ADR	$177.7M	— (loss-making)	12.8×	+40.84% (above 0%: growing)	n/m	−798.37% (below 0%: shrinking)	44.11%	(8.64%)	Compare
DH Definitive Healthcare Corp.	$163.7M	— (loss-making)	— (loss-making)	−8.99% (below 0%: shrinking)	n/m	−32.60% (below 0%: shrinking)	77.27%	(9.09%)	Compare
OPRX OptimizeRx Corp.	$163.3M	35.8×	41.7×	−29.77% (below 0%: shrinking)	n/m	+89.86% (above 0%: growing)	76.51%	(0.43%)	Compare
HCAT Health Catalyst, Inc.	$112.9M	— (loss-making)	— (loss-making)	−26.26% (below 0%: shrinking)	n/m	+65.58% (above 0%: growing)	42.71%	89.08%	Compare
LFMD LifeMD, Inc.	$110.4M	— (loss-making)	— (loss-making)	−3.55% (below 0%: shrinking)	n/m	−247.52% (below 0%: shrinking)	88.82%	(15.08%)
CCLD CareCloud, Inc.	$91.8M	16.5×	11.0×	+8.56% (above 0%: growing)	+150.00% (above 0%: growing)	−0.44% (below 0%: shrinking)	50.46%	19.50%	Compare
Median of peers	$170.7M	16.5×	14.5×	−5.77%	—	+35.54%	63.36%	4.33%

All 44 Health Information Services stocks →

Pay and ownership Proxy statement filed 30 April 2026

Chief executive’s pay

Year	Total pay	Actually paid	$100 invested
2025	777.08k	777.08k	52.22
2024	1.06m	1.06m	63.06
2023	888.80k	948.30k	105.61

Ownership

Directors and executive officers, together 17.22%

Justin Schreiber 5.68%

BlackRock, Inc. 5.21%

Total pay is as the Summary Compensation Table states it; actually paid revalues the year’s share awards at its end, as the SEC’s pay-versus-performance rule asks. $100 invested is what $100 in the company’s shares at the start of the earliest year shown was worth at each year’s end. Ownership is the proxy’s own table: the directors and officers as a group, and every holder of 5% or more. Read the proxy statement

LifeMD, Inc. (LFMD) Latest News

5 Nov

Impact 3 · 7:30 AM · GlobeNewswire

LifeMD expands access to Lilly’s self-pay GLP-1 medicines, enabling option to dispense and ship directly to patients nationwide

20 Oct

Impact 3 · 4:05 PM · GlobeNewswire

LifeMD to Report Third Quarter 2026 Financial Results on November 9

20 Sep

Impact 4 · 2:43 PM

LifeMD (LFMD) Secures AT&T Partnership. Can Free Memberships Produce Paying Patients?

17 Sep

Impact 3 · 5:13 PM

AT&T (T) Adds Cricket 5G Home Internet And Free Virtual Care

16 Sep

Impact 3 · 11:13 AM

AT&T Teams Up With LifeMD for Virtual Health Care: Can it Aid Shares?

15 Sep

Impact 4 · 9:00 AM

AT&T Becomes the First and Only Carrier to Offer Free Access to Virtual Healthcare Powered by LifeMD

23 Aug

Impact 3 · 1:09 AM

LifeMD (LFMD) Stock Sees Fair Value Cut After Analysts Lower Targets On Weaker Guidance

12 Aug

Impact 4 · 8:13 PM · The Motley Fool transcript

LifeMD (LFMD) Q2 2026 Earnings Call Transcript

6 Aug

Impact 4 · 8:30 AM · Moby transcript

LifeMD, Inc. Q2 2026 Earnings Call Summary

5 Aug

Impact 4 · 7:45 PM

UPDATE - LifeMD Reports Second Quarter 2026 Results

Impact 4 · 4:11 PM

LifeMD Reports Second Quarter 2026 Results

Impact 3 · 11:03 PM · MarketBeat transcript

LifeMD Q2 Earnings Call Highlights

Impact 3 · 8:35 PM

LifeMD, Inc. (LFMD) Reports Q2 Loss, Lags Revenue Estimates

3 Aug

Impact 3 · 8:03 PM · MarketBeat transcript

Medifast Q2 Earnings Call Highlights

22 Jun

Impact 4 · 8:00 AM · GlobeNewswire

LifeMD Announces Exclusive Collaboration to Launch Direct-to-Patient Self-Pay Program for XYOSTED® (testosterone enanthate) Injection

18 May

Impact 4 · 4:23 PM · Bloomberg

GLP-1 Users Turn to Telehealth to Access Weight Loss Drugs

7 May

Impact 4 · 8:30 AM · Moby

LifeMD, Inc. Q1 2026 Earnings Call Summary

6 May

Impact 4 · 10:16 PM · MarketBeat

LifeMD Q1 Earnings Call Highlights

Impact 4 · 6:16 PM · The Motley Fool transcript

LifeMD (LFMD) Q1 2026 Earnings Transcript

Impact 4 · 4:05 PM · GlobeNewswire

LifeMD Reports First Quarter 2026 Results

Impact 3 · 6:30 PM · Zacks

LifeMD, Inc. (LFMD) Reports Q1 Loss, Tops Revenue Estimates

2 May

Impact 4 · 3:18 PM · Simply Wall St.

How The LifeMD (LFMD) Story Is Shifting Around GLP-1 Growth And 2026 Expectations

21 Apr

Impact 3 · 10:45 AM · MarketBeat

Quest Diagnostics Q1 Earnings Call Highlights

Impact 3 · 8:00 AM

LifeMD (LFMD) Soars 23.7%: Is Further Upside Left in the Stock?

17 Apr

Impact 4 · 1:05 PM · Simply Wall St.

How The LifeMD (LFMD) Story Is Shifting Around GLP-1 Growth Plans And 2026 Expectations

10 Apr

Impact 4 · 8:15 AM

LifeMD® Now Offering Eli Lilly and Company’s Foundayo™ (orforglipron), a New GLP-1 Pill for Weight Management

31 Mar

Impact 4 · 9:15 AM · qz.com

Novo Nordisk launches Wegovy subscription program

Impact 4 · 8:45 AM · GlobeNewswire

LifeMD Offers Novo Nordisk's Industry-First Wegovy® Telehealth Subscription Program

Impact 4 · 8:33 AM · The Wall Street Journal

Novo Nordisk Launches Discounted Subscription Program for Wegovy Obesity Drugs

Impact 4 · 7:46 AM · PR Newswire

Novo Nordisk launches first and only multi-month subscription program for FDA-approved Wegovy®, offering savings of up to $1,200/year

LifeMD, Inc.

Insider Decisions last twelve months

Capital & Financial Ratios $m

Valuation vs history

Dividends

Assets vs Liabilities $m

Compound Annual Growth %

Earnings Trends EPS, adjusted, against the consensus

EPS $

Revenue $m

Operating Cash Flow $m

Free Cash Flow $m

Target Price Range

Recommendation Rating

Ten years at a glance Fiscal years to December

LifeMD, Inc. vs peers in Health Information Services (Q) = latest quarter vs a year earlier

Pay and ownership Proxy statement filed 30 April 2026

Chief executive’s pay

Ownership

LifeMD, Inc. (LFMD) Latest News

5 Nov

20 Oct

20 Sep

17 Sep

16 Sep

15 Sep

23 Aug

12 Aug

6 Aug

5 Aug

3 Aug

22 Jun

18 May

7 May

6 May

2 May

21 Apr

17 Apr

10 Apr

31 Mar

Insider Decisions last twelve months

Capital & Financial Ratios $m

Valuation vs history

Dividends

Assets vs Liabilities $m

Compound Annual Growth %

Earnings Trends EPS, adjusted, against the consensus

EPS $

Revenue $m

Operating Cash Flow $m

Free Cash Flow $m

Target Price Range

Recommendation Rating

Ten years at a glance Fiscal years to December

LifeMD, Inc. vs peers in Health Information Services (Q) = latest quarter vs a year earlier

Pay and ownership Proxy statement filed 30 April 2026

Chief executive’s pay

Ownership

LifeMD, Inc. (LFMD) Latest News

5 Nov

20 Oct

20 Sep

17 Sep

16 Sep

15 Sep

23 Aug

12 Aug

6 Aug

5 Aug

3 Aug

22 Jun

18 May

7 May

6 May

2 May

21 Apr

17 Apr

10 Apr

31 Mar

Stockrow Weekly